Veterinary World


ISSN (Online): 2231-0916


 Editorial board

 Instructions for authors

 Reviewer guideline

 Open access policy




Open Access

Copyright: The authors. This article is an open access article licensed under the terms of the Creative Commons Attribution License ( which permits unrestricted use, distribution and reproduction in any medium, provided the work is properly cited.

Research (Published online : 23-09-2013)

3. Preparation of Foot and Mouth Disease trivalent vaccine type A, O, SAT2 with determination of the Guinea pig protective dose 50 (GPPD50) - Hind M. Daoud, Ehab El-Sayed Ibrahim, Wael Mossad Gamal El-Din and Amr Ismail Hassan Hassanin

Veterinary World, 6(11): 844-851


1. Depa, P.M., Dimri, U., Sharma, M.C. and Tiwari, R. (2012) Update on epidemiology and control of Foot and Mouth Disease - A menace to international trade and global animal enterprise, Vet. World, 5(11): 694-704.
2. Knowles, N.J. and Samuel, A.R. (2003) Molecular epidemiology of foot-and-mouth disease virus. Virus Res.,91(1): 65-80.
3. Ko, Y.J., Jeoung, H.Y., Lee, H.S., Chang, B.S., Hong, S.M., Heo, E.J., Lee, K.N., Joo, H.D., Kim, S.M., Park, J.H. and Kweon, C.H. (2009) A recombinant protein-based ELISA for detecting antibodies to foot-and-mouth disease virus serotype Asia 1. J. Virol. Methods, 159(1): 112-118.
4. Belsham, G.J. (1993) Distinctive features of FMDV, a member of the Picorna virus family, aspects of virus protein synthesis, protein processing and structure. Progress in Biophysics and Molecular Biology, 60: 241-260.
5. Paton, D.J., Valarcher, J.F. and Bergmann, I. (2005) Selection of foot and mouth disease vaccine strains – a review. Rev. Sci. Tech., 24(3): 981–993.
6. Cartwright, B., Brown, F. and Chapman, W. G. (1980) Serological and immunological relationships between the 146S and 12S particles of foot-and-mouth disease virus. Journal of General Virology, 50: 369-375.
7. Aidaros, H.A. (2002) Regional status and approaches to control and eradication of FMD in the Middle East and North Africa. Rev. Sci. Tech.Off.Int. Epiz., 21 (3): 451-458.
8. Knowles Nick, J., Wadsworth, J., Reid, S.M., Swabey, K.G., El-Kholy, A.A., Abd El-Rahman, A.O., Soliman, H. M., Ebert, K., Ferris, N.P., Hutchings, G.H., Statham, R.J.,King, D.P. and Paton, D.J. (2007) Foot-and-Mouth Disease Virus Serotype A in Egypt. Emerg Infect Dis., 13(10): 1593–1596.
PMid:18258017 PMCid:PMC2851527
9. FAO (2012) Foot-and-Mouth disease caused by serotype SAT2 in Egypt and Libya: a regional concern for animal health in North Africa and the Middle East. EMPRES WATCH, Vol. 25, March 2012.
10. Shawky, M., Abd El-Aty, M., Fakry, H.M., Daoud, H.M., Ehab El-Sayed, I., Wael Mossad, G., Rizk, S.A., Abu-Elnaga, H., Mohamed, A. A., Abd El-kreem, A. and Farouk, E. M. (2013) Isolation and Molecular Characterization of Foot and Mouth Disease SAT2 Virus during Outbreak 2012 in Egypt. J Vet Adv, 3(2): 60-68.
11. Crowther, J.R., Reckziegel, P.O. and Prado, J.A. (1995) Quantification of whole virus particles (146S) of foot-and- mouth disease virus in the presence of virus subunits (12S), using monoclonal antibodies in a sandwich ELISA. Vaccine, 13(12): 1064–1075.
12. Shiari, J., Chatchawanchonteera, A., Sinsuwongwat, W., Makarasen, P. and Sugimura, T. (1990) Estimation of 140S particles in FMD virus vaccine by using the computer analyzing system.Jap. J. Vet. Sci., 52(3): 621- 630.
13. Alkan M., S. Gurcan, M. F. Sarac, Y. Gultekin, A. Arslan, E. Uzunlu, S. Akyuz and G.Aynagoz (2008) Development of a Foot and Mouth disease vaccine potency tests without conducting animal challenge experiment. The Global control of FMD - Tools, ideas and ideals – Erice, Italy 14-17 October 2008, pp.181-186.
14. OIE (2012) FMD, Chapter 2.1.5. In manual of Standard for Diagnostic Test and Vaccine, Paris, pp.77-92.
15. Richard C. Knudsen, Christopher M. Groocock, and Arthur A. Andersen (1979) Immunity to Foot-and-Mouth Disease Virus in Guinea Pigs: Clinical and Immune Responses. Infection and Immunity, 24(3): 787-792.
PMid:223986 PMCid:PMC414375
16. EL-Garf, E.M. (2012) Using of guinea Pigs as animal model to determine the PD50 of local oil bivalent FMD vaccine. 7th Int. Sci. Conf., Mansoura 28-30 August. pp. 797-809.
17. Black, L., Francis, M.J., Rweyemamu, M.M., Umehara, O. and Boge, A. (1985) "The relationship between serum antibody titers and protection from foot and mouth disease in pigs after oil emulsion vaccination". J. Biol. Stand., 12(4): 379-389.
18. Huang, X., Li, Y., Fang, H. and Zheng, C. (2011) Establishment of persistent infection with foot and mouth disease virus in BHK-21 cells. Virology Journal, 8: 169.
PMid:21492421 PMCid:PMC3097150
19. Reed, L.J. and Muench, H. (1938) A simple method for estimating fifty percent (50%) end points. Amer. J. Hyg., 27: 493-497.
20. Traub, E. and Manso, I.R. (1944) Uber die herstellung complement bindender merrsch-weinehon sera fur die typen diagnose bie Maul und Klauenseuche. Zbi. Bakt. Lorig., 151:380-381.
21. Health protection Agency (2009) Complement fixation tests. Issue no:3 Issue date 11.12.09 Issued by: standards unit, Department for Evaluations, standards and Training, page 1 of 23.
22. Rizk, S. (2007) Studies on the preparation of an improved Foot and Mouth Disease oil vaccine. Ph. D. Thesis, University of Cairo.
23. Killington, P.A., Stokes, A. and Hierolzer (1996) Virology Methods Manual; Chapter 4: 72-89.
24. Barteling, S.J. and Cassim, N.I. (2004) Very fast (and safe) inactivation of foot-and-mouth disease virus and enteroviruses by a combination of binary ethyleneimine and formaldehyde. Dev Biol. (Basel),119: 449-55.
25. Ali, S.M., Abd El-Aty, M.M., Elnakashly,S.A. and El- Kilany,A.S. (2009) "Inactivation of FMDV (Type O and A) by using a combination of binary ethyleneamine and Formaldehyde". 3rd Sci. Cong., Faculty of Kafr El-Sheik, pp. 962-973.
26. Doel, T.R. and Chong, W.K.T., (1982) Comparative immunogenicity of 146s, 75s, and 12s particles of FMDV. Arch. Virol., 73: 185-191.
27. Bartelling, A.S.J., Van Maanan, C., Yadin, H. and Anemaet, D.A.J. (1990) A Foot and Mouth Disease vaccine bank; purified inactivated antigen stored at ultra-low temperatures for the rapid preparation of double oil emulsion vaccines. Eurpean commission for control of Foot and Mouth Disease. Session of Research Group of the standing technical Committee, Lindholm, 1990, pp. 172-177.
28. Gamil, M.A. (2010) Studies on the immune response of calves vaccinated inactivated bivalent FMD virus vaccine type O1 and A Egypt 2006. M.V.Sc in Veterinary Science (virology). Benha University.
29. El-Sayed, E., Gamal El-Din, W.M.,Rizk, S.A. and Abd El- Aty, M. (2012) Effect of Different Storage Temperatures on the Efficacy of the Bivalent Foot and Mouth Disease Oil Vaccine. Journal of Advanced Veterinary Research, 2:198-205.
30. Assem, A. M. (2010) Trial for preparation of bivalent oil adjuvant FMD vaccine. Ph. D Faculty of Veterinary Medicine, Department of Microbiology Alexandria University.
31. Ferreira, M.E.V. (1976) Microtitre neutralization test for the study of FMD antibodies. Bol. Centro Pan Americano de Fiebre Aftosa, 21: 22-23.
32. Parida, S. (2009) Vaccination against foot-and-mouth disease virus: strategies and effectiveness Expert Rev. Vaccines 8(3): 347–365.
33. Ibrahim, E.E. (2011) Advanced studies on Foot and Mouth Disease Vaccines of sheep in Egypt. Ph D.Sc. Thesis (Infectious Diseases), Faculty of Veterinary Medicine, Cairo University, Egypt.
34. Ahmed, H.A., Salem, S.A., Habashi, A.R., Arafa, A.A., Aggour, M.G., Salem, G.H., Gaber, A.S., Selem, O., Abdelkader, S.H., Knowles, N.J., Madi, M., Valdazo- Gonzlez, B.,Wadsworth, J., Hutchings, G.H., Mioulet, V., Hammond, J.M., King, D.P. (2012) Emergence of foot-and- mouth disease virus SAT 2 in Egypt during 2012. Transbound Emerg Dis.,59(6):476-481.
35. Brown, F. (1992) New approaches to vaccination against foot-and-mouth disease. Vaccine, 10:1022–1026.
36. Motamedi Sedeh. F., Khorasani, A., Shafaee, K., Salehizadeh, M., Fatolahi, H., Arbabi, K., Daneshvari, S. and Abhari, M. (2007) Immune response of Foot and Mouth Disease Virus Type A87/IRN Inactivated vaccine by gamma irradiation on Guinea Pig in Iran, Iranian Journal of Science & Technology, Transaction A, 31 (A1): 35-41.
37. Pay, T.W.F. and Hingley, P.J. (1987) Correlation of 140 S antigen dose, the serum-neutralising antibody response and the level of protection induced in cattle by foot-and-mouth disease vaccines. Vaccine,5:60-64.
38. Morgan, D.O., Bachrach, H.L. and McKercher, P.D. (1969) Immunogenicity of nanogram to milligram quantities of inactivated foot-and-mouth disease virus. Part I. Relative virus-neutralising potency in guinea pig sera. Appl Microbiol., 17(3): 441–445.
PMid:4305396 PMCid:PMC377708
39. Barnett, P.V., Pullen, L., Warder, P. and Stathen, R. (1998) International bank for foot and mouth disease vaccine (preliminary studies on emergency foot and mouth disease vaccines formulated with montanide IMS -Immunosol-, a new concept in oil adjuvancy. European Commission for the Control of FMD, Aldershot, United Kingdom, 14-18 September 1998, Appendix 37: 268-271.
40. El-Sayed, E., Mossad, W., Ali, S.M. and Shawky, M. (2012) Studies on the duration of immunity induced in cattle after natural FMD infection and post vaccination with bivalent oil vaccine, Vet World, 5(10): 603-608.